Established in 1896 and headquartered in Basel, Switzerland, Roche has business operations in more than 150 countries and has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics.
Based on the strategic alliance with Roche, Chugai Pharmaceutical Co., Ltd. merged with Nippon Roche, and Roche acquired a majority of Chugai Pharmaceutical Co., Ltd.’s stock. Roche holds 59.89% of Chugai Pharmaceutical Co., Ltd.’s outstanding shares and Chugai Pharmaceutical Co., Ltd. adopted a new business model. Under this model, Chugai Pharmaceutical Co., Ltd. maintained both its name, CEO, and management autonomy, and both parties agreed to keep Chugai Pharmaceutical Co., Ltd. as a listed company on the Prime Market of the Tokyo Stock Exchange.
The strategic alliance provides Chugai Pharmaceutical Co., Ltd. with exclusive rights to develop and market Roche products in Japan. In addition, Chugai Pharmaceutical Co., Ltd. gains access to a worldwide footprint for its in-house products by out-licensing them to Roche, who can then market them to their global market.
Development Pathways
Chugai Pharma U.S.A., Inc. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharma U.S.A. Inc. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following “Terms and Conditions of Website Use.”
Copyright © 2023 Chugai Pharma U.S.A. Inc. All rights reserved.
